Please assess the completion status of the following clinical trial:

Trial Title: BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed aggressive \[de novo or transformed\] NHL according to REAL/WHO classification.~* At least one objectively measurable lesion as demonstrated by CT, spiral CT, or MRI and plain radiograph of the chest (chest x-ray, for chest lesions only) that can be followed for response as target lesion.~* Relapse after 2 or more prior regimens of chemotherapy~* ECOG performance status of 0, 1, or 2~* Adequate hematologic, renal and hepatic function~* LVEF ≥50% determined by MUGA scan~Exclusion Criteria:~* Prior treatment with a cumulative dose of doxorubicin or equivalent exceeding 450 mg/m²~* Prior allogenic stem cell transplant~* Histological diagnosis of Burkitt lymphoma, lymphoblastic lymphoma or Mantle cell lymphoma~* Active CNS lymphoma or HIV-related lymphoma.~* Any chemotherapy, radiotherapy, or other anticancer treatment (including corticosteroid, 10 or more mg/day of prednisone or equivalent) within the 2 weeks before randomization~* Pregnant women or nursing mothers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental Arm (Type: EXPERIMENTAL): Pixantrone (BBR2778)
- Comparator Arm (Type: ACTIVE_COMPARATOR): To be chosen by the investigator, among vinorelbine, oxaliplatin, ifosfamide, etoposide or mitoxantrone

Based on this trial design, predict the completion outcome and termination type (if applicable).